Document Detail

The rationale for thrombolytic therapy.
MedLine Citation:
PMID:  11823999     Owner:  NLM     Status:  MEDLINE    
Substantial progress has been made toward understanding the pathophysiological processes that lead to acute myocardial infarction. Research has shown that the mechanism of infarction is the rupture of an atherosclerotic plaque with a subsequent thrombogenic response from exposed subendothelial tissue, leading to additional or complete obstruction of the vessel. Myocardial cell death then proceeds in a wavefront fashion from the subendocardium to the epicardium. Time to myocardial reperfusion and the extent of collateral flow are the primary determinants of final infarct area. This knowledge led to the development of therapeutic strategies to achieve early and sustained reperfusion of the infarct-related vessel, the presumption being that this would result in increased myocardial salvage and better residual left ventricular function in addition to reductions in infarct expansion and electrical instability. The results of several large thrombolytic trials have supported this model, showing that patients who receive thrombolytic therapy derive a constant relative survival benefit when compared with control patients. The largest comparative thrombolytic trial to date has shown that therapies that result in early, more complete reperfusion are indeed associated with lower mortality; however, these therapies may be associated with higher rate of complications such as intracranial haemorrhage and reocclusion. Future evaluations must include assessment of the benefits relative to the risks of newer, more potent thrombolytic regimens.
R M Califf
Related Documents :
7480969 - Treatment of myocardial infarction: hypotensive effect of different thrombolytic agents.
8034869 - Eligibility for and benefit of thrombolytic therapy in inferior myocardial infarction: ...
1900139 - Pericardial effusion after intravenous recombinant tissue-type plasminogen activator fo...
3097099 - Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate ...
8418769 - Antiplatelet therapy in coronary heart disease. emerging strategies for the treatment a...
1960329 - Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen...
2886039 - Ischemic heart disease: a patient-specific therapeutic approach with emphasis on qualit...
23559909 - Thrombolysis in the age of primary percutaneous coronary intervention: mini-review and ...
23890399 - Effects of biventricular pacing on left heart twist and strain in a porcine model of r...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European heart journal     Volume:  17 Suppl E     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1996 Sep 
Date Detail:
Created Date:  2002-02-04     Completed Date:  2002-02-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  2-8     Citation Subset:  IM    
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Fibrinolytic Agents / therapeutic use*
Models, Theoretical
Myocardial Infarction / drug therapy*,  mortality,  physiopathology*
Myocardial Reperfusion
Survival Analysis
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction.
Next Document:  Thrombolytic therapy in Europe: current status.